Clinical trial
XELOX for Metastatic Breast Cancer
NCT00204776 · University of Wisconsin, Madison, Other · Completed
Key facts
| NCT number | NCT00204776 |
|---|---|
| Title | XELOX for Metastatic Breast Cancer |
| Official title | A Phase II Trial of Capecitabine and Oxaliplatin in Metastatic Breast Cancer |
| Lead sponsor | University of Wisconsin, Madison, Other |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine and Oxaliplatin |
| Enrollment | 37 |
| Start date | Mar 1, 2005 |
| Completion | Nov 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Dec 12, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: